ReviewCancers2021
Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.Cancer immunology research · 2024Trial
- Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial.World journal of gastroenterology · 2023Trial
- Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.Frontiers in immunology · 2021Trial
- Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients.Molecular oncology · 2026Article
- Efficacy and Safety of Radiotherapy Combined with PD-1 Inhibitors and Targeted Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective, Real-World Multicenter Study.Journal of hepatocellular carcinoma · 2026Article
- Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study.JTO clinical and research reports · 2025Article
- Spatially optimized 125I brachytherapy: a novel immunomodulatory approach based on spatially fractionated radiation therapy principles.Frontiers in oncology · 2025Article
- Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy.Therapeutic advances in medical oncology · 2025Review
- Severe immune-mediated hepatitis caused by sindilizumab combined with local radiotherapy: a case report.European journal of hospital pharmacy : science and practice · 2024Article
- Radiation therapy for cancer is potentially associated with reduced growth of concomitant abdominal aortic aneurysm.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Hypofractionated radiotherapy with simultaneous integrated boost for localized prostate cancer patients: effects on immune system and prediction of toxicity.Frontiers in immunology · 2024Article
- Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio.Clinical and translational radiation oncology · 2024Review
- Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.BMC cancer · 2023Article
- Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.Frontiers in immunology · 2023Article
- Application of injectable hydrogels in cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy.Neoplasia (New York, N.Y.) · 2022Article
- Immunomodulation by radiotherapy in tumour control and normal tissue toxicity.Nature reviews. Immunology · 2022Review
- Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment.Frontiers in immunology · 2022Review
- Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Radiotherapy (RT) is highly effective at directly killing tumor cells and plays an important part in cancer treatments being delivered to around 50% of all cancer patients. The additional immunomodulatory properties of RT have been investigated, and if exploited effectively, have the potential to further improve the efficacy of RT and cancer outcomes. The initial results of combining RT with immunomodulatory agents have generated promising data in pre-clinical studies, which has in turn led to a large number of RT and immunotherapy clinical trials. The overarching aim of these combinations is to enhance anti-tumor immune responses and improve responses rates and patient outcomes. In order to maximize this undoubted opportunity, there remain a number of important questions that need to be addressed, including: (i) the optimal RT dose and fractionation schedule; (ii) the optimal RT target volume; (iii) the optimal immuno-oncology (IO) agent(s) to partner with RT; (iv) the optimal site(s)/route(s) of administration of IO agents; and finally, the optimal RT schedule. In this review, we will summarize progress to date and identify current gaps in knowledge that need to be addressed in order to facilitate effective clinical translation of RT and IO agent combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.